StockData
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. (ALDX) stock

ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.69+0.02 (+3.63%)

Close on Nov 17, 2026Market cap $41.86MP/E –Yield –

Aldeyra Therapeutics cash

Cash and short-term investments held at the end of each period.

Aldeyra Therapeutics's cash was $45.09M at Jun 30, 2026. For fiscal 2025 it was $70.04M, down 30.8% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $229.79M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$70.04M-30.8%
FY2024Dec 31, 2024$101.15M-29.2%
FY2023Dec 31, 2023$142.82M-18.1%
FY2022Dec 31, 2022$174.30M-24.1%
FY2021Dec 31, 2021$229.79M+195.1%
FY2020Dec 31, 2020$77.86M+75.3%
FY2019Dec 31, 2019$44.43M-6.2%
FY2018Dec 31, 2018$47.36M+136.5%
FY2017Dec 31, 2017$20.02M-19.6%
FY2016Dec 31, 2016$24.90M-9.8%
FY2015Dec 31, 2015$27.60M+223.7%
FY2014Dec 31, 2014$8.53M+161.4%
FY2013Dec 31, 2013$3.26M+166.6%
FY2012Dec 31, 2012$1.22M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$45.09M-45.0%
Q1 FY2026Mar 31, 2026$65.00M-27.8%
Q4 FY2025Dec 31, 2025$70.04M-30.8%
Q3 FY2025Sep 30, 2025$75.30M-33.2%
Q2 FY2025Jun 30, 2025$81.92M-31.9%
Q1 FY2025Mar 31, 2025$90.06M-32.3%
Q4 FY2024Dec 31, 2024$101.15M-29.2%
Q3 FY2024Sep 30, 2024$112.74M-21.3%
Q2 FY2024Jun 30, 2024$120.33M-20.7%
Q1 FY2024Mar 31, 2024$133.04M-19.4%
Q4 FY2023Dec 31, 2023$142.82M-18.1%
Q3 FY2023Sep 30, 2023$143.33M-22.7%
Q2 FY2023Jun 30, 2023$151.68M-22.9%
Q1 FY2023Mar 31, 2023$165.03M-23.9%
Q4 FY2022Dec 31, 2022$174.30M-24.1%
Q3 FY2022Sep 30, 2022$185.33M-23.2%
Q2 FY2022Jun 30, 2022$196.69M-21.2%
Q1 FY2022Mar 31, 2022$216.87M+56.6%
Q4 FY2021Dec 31, 2021$229.79M+195.1%
Q3 FY2021Sep 30, 2021$241.37M+180.1%
Q2 FY2021Jun 30, 2021$249.74M+311.5%
Q1 FY2021Mar 31, 2021$138.44M+259.2%
Q4 FY2020Dec 31, 2020$77.86M+75.3%
Q3 FY2020Sep 30, 2020$86.18M+13.1%
Q2 FY2020Jun 30, 2020$60.69M-12.6%
Q1 FY2020Mar 31, 2020$38.54M-53.1%
Q4 FY2019Dec 31, 2019$44.43M-6.2%
Q3 FY2019Sep 30, 2019$76.17M+323.0%
Q2 FY2019Jun 30, 2019$69.46M+182.3%
Q1 FY2019Mar 31, 2019$82.12M+310.1%
Q4 FY2018Dec 31, 2018$47.36M+43.1%
Q3 FY2018Sep 30, 2018$18.01M+23.3%
Q2 FY2018Jun 30, 2018$24.61M+27.5%
Q4 FY2017Dec 31, 2017$20.02M-19.6%
Q3 FY2017Sep 30, 2017$33.10M+127.2%
Q2 FY2017Jun 30, 2017$14.61M-17.0%
Q1 FY2017Mar 31, 2017$19.30M–
Q4 FY2016Dec 31, 2016$24.90M–
Q3 FY2016Sep 30, 2016$14.57M–
Q2 FY2016Jun 30, 2016$17.61M–

More Aldeyra Therapeutics figures

See a number that looks wrong?